03Jan/13

Veloxis' Phase 3 Trial of LCP-Tacro in Stable Kidney Transplant Patients … – GlobeNewswire (press release)

Veloxis’ Phase 3 Trial of LCP-Tacro in Stable Kidney Transplant Patients
GlobeNewswire (press release)
Non-inferiority was determined by a composite endpoint, measured over a year of follow up that included death, graft failure, biopsy-proven acute rejection or loss to follow-up. Results of this trial demonstrated that patients can be successfully

and more »

31Dec/12

Newlink Genetics' Pancreatic Cancer Vaccine Likely To Disappoint Investors In … – Seeking Alpha

Newlink Genetics’ Pancreatic Cancer Vaccine Likely To Disappoint Investors In
Seeking Alpha
Alpha-Gal residues are powerful antigens that cause a rapid, hyperacute rejection response whenever foreign tissues bearing them are introduced into the human body. Thus the goal of the Hyperacute(R) platform is to train the patient’s immune system to

28Dec/12

Biomarkers could give early warning of late heart transplant rejection – HealthCanal.com

Biomarkers could give early warning of late heart transplant rejection
HealthCanal.com
Boston, Mass.—Researchers at Boston Children’s Hospital have found a combination of biomarkers related to blood vessel and tissue injury that, when measured together, could signal when a transplanted heart is becoming damaged to the point of failure,

and more »